A Global Leader in LAG-3 Immunotherapy for Cancer and Autoimmune Diseases

Immutep is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. We are pioneers in the understanding and advancement of theraeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.

Our LAG-3 immunotherapies are distinctly designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease.

Latest press releases.

Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

March 23rd 2023
press releases

Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer

March 14th 2023
press releases

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

February 6th 2023
press releases
more

About us.

our science.

Utilizing our LAG-3 expertise, we’re focused on safely delivering on immunotherapy’s promise to drive superior clinical outcomes for patients.

our pipeline.

We have three clinical-stage & two earlier stage candidates, reflecting our unique ability to harness the LAG-3 immune checkpoint in multiple ways to stimulate the immune system.

investors & media.

We are dedicated to leveraging our technology to develop innovative treatment options for patients and to maximise value to shareholders. Learn more.